CoChat
Sign Up
Cited by 113Gestational Diabetes Research and ManagementPregnancy and Medication ImpactDiabetes Treatment and Management

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.

Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: A systematic review

Lautatzis, Maria-Elena, Goulis, Dimitrios G., Vrontakis, Maria·2013·Metabolism
DOI 10.1016/j.metabol.2013.06.006
Open this paper in CoChat — free account

Abstract

Background Metformin is an effective oral anti-hyperglycemic agent that is widely used to manage diabetes mellitus type 2 in the general population and more recently, in pregnancy. However, as metformin crosses the placenta, its use during pregnancy raises concerns regarding potential adverse effects on the mother and fetus.Objective (i) To provide background for the use of metformin during pregnancy through a narrative review and (ii) to critically appraise the published evidence on the efficacy and safety of using metformin during pregnancy through a systematic review.Results Metformin appears to be effective and safe for the treatment of gestational diabetes mellitus (GDM), particularly for overweight or obese women. However, patients with multiple risk factors for insulin resistance may not meet their treatment goals with metformin alone and may require supplementary insulin. Evidence suggests that there are potential advantages for the use of metformin over insulin in GDM with respect to maternal weight gain and neonatal outcomes. Furthermore, patients are more accepting of metformin than insulin. The use of metformin throughout pregnancy in women with polycystic ovary syndrome reduces the rates of early pregnancy loss and preterm labor and protects against fetal growth restriction. There have been no demonstrable teratogenic effects, intra-uterine deaths or developmental delays with the use of metformin.Conclusions The publications reviewed in this paper support the efficacy and safety of metformin during pregnancy with respect to immediate pregnancy outcomes. Because there are no guidelines for the continuous use of metformin in pregnancy, the duration of treatment is based on clinical judgment and experience on a case-by-case basis.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.metabol.2013.06.006

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 113

Related

See all

Metadata

Authors
Lautatzis, M.-E., Goulis, D. G., & Vrontakis, M.
Affiliations
  • Aristotle University of Thessaloniki (GR)
  • University of Manitoba (CA)
Corresponding author
Lautatzis, Maria-Elena
ORCID
Venue
Metabolism
Publisher
Elsevier BV
Published
2013-11
Volume
62
Issue
11
Pages
1522-1534
ISSN
0026-0495 (ISSN-L)
DOI
10.1016/j.metabol.2013.06.006
OpenAlex
W1979876574
Cited by
113
References
77
Citations by year
2026: 1 · 2025: 4 · 2024: 9 · 2022: 4 · 2021: 8 · 2020: 8 · 2019: 9 · 2018: 13 · 2017: 9 · 2016: 14 · 2015: 14 · 2014: 18 · 2013: 2
FWCI
2.75
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
metformin, pregnancy, gestational diabetes mellitus, polycystic ovary syndrome, drug safety, teratogenicity, fetal growth restriction, preterm labor, miscarriage, gestational weight gain, neonatal outcomes, insulin resistance, insulin therapy comparison, maternal-fetal drug transfer
MeSH terms
Adult, Clinical Trials as Topic, Female, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Metformin, Obesity, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Diabetes, Gestational, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review